LAR comprehensively reflects the nutritional status and systemic inflammation by integrating serum LDH and Alb, which might be promising hematological biomarkers for advanced NSCLC receiving PD-1 inhibition plus chemotherapy with or without antiangiogenic therapy. This evidence concerns the gene ALB and non-small cell lung carcinoma.